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 The Human kinome includes between 500-600 known kinases and open reading frames (ORFs) 
that play key roles in regulating many cellular processes. Some of these cellular processes 
include, signal transduction, metabolism, transcription, cell cycle progression, cell movement, 
apoptosis, differentiation and protein phosphorylation. Various protein and lipid kinases have 
previously been shown to control viral life cycles. The lipid kinase PI4KIIIA was found to be 
required for hepatitis C virus (HCV) replication in several genomic screens using small 
interference RNAs that target human kinases.  Although such a loss-of-function approach has led 
to the identification of host cell factors that are required for HCV replication, no kinases have 
been found with respect to antiviral activity.  Here we adopt a genomic approach to identify 
human kinases that negatively regulate HCV infection. To this end, a library of activated kinases, 
which consists of 192 human kinases and kinase-related ORFs, was cloned into a retroviral 
vector, which adds a myristoylation sequence and flag-epitope tag to each ORF. Using an 
overexpression screening approach, we identified that several kinases, including Cyclin-
dependent kinases regulatory subunit 1 (CKS1B), Mitogen-activated protein kinase kinase 5 
(MAP2K5) and Protein kinase C and casein kinase substrate in neurons 1 (PACSIN1), potently 
suppressed HCV infection.  The expression of these active kinases did not activate the nuclear 
factor-kappaB (NF-κB) pathway or the production of type I interferon and interferon-stimulated 
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genes (ISGs), instead they acted at different post-entry stages. Specifically, CKS1B significantly 
inhibited viral RNA replication; MAP2K5 also suppressed virus replication and appeared to 
exert additional inhibition after replication.  PACSIN1, by contrast, inhibited HCV infection via 
a yet-to-be-defined mechanism.  
 
          Public Health significance: Hepatitis C occurs worldwide and is the major cause of liver 
diseases. Approximately three quarters of people infected with HCV become chronic carriers of 
the virus and of these chronically infected, majority of the patients develop liver cirrhosis and 
hepatocellular carcinoma. Current treatments available to patients are costly and cause severe 
side-effects that result in poor patient compliance. Thus, the inhibitory effects as shown here by 
targeting kinases, shows the potential of combating HCV infection by activating specific kinase-
mediated pathways, which would be an alternative method of treatment of these patients.  
 
 v 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ........................................................................................ ........... XIII 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 HEPATITIS C VIRUS ........................................................................................ 1 
1.1.1 HEPATITIS C VIRUS BURDEN AND DISEASE .................................... 1 
1.1.2 HCV GENOME ............................................................................................ 3 
1.1.3 HCV LIFE CYCLE ...................................................................................... 4 
1.1.4 HCV ASSEMBLY AND LIPID DROPLETS ............................................ 6 
1.1.5 CELL LINES TO STUDY HCV ................................................................. 7 
1.1.5.1 CELL LINES PERMISSIVE FOR HCV REPLICATION .............. 8 
1.1.5.2 DEVELOPMENT OF HCV REPLICONS......................................... 9 
1.2 KINOME ............................................................................................................ 10 
1.2.1 CLASSIFICATION OF THE HUMAN KINOME ................................. 11 
1.2.2 KINASES ..................................................................................................... 13 
1.2.2.1 MYRISTOYLATION ......................................................................... 13 
1.2.2.2 HEPATITIS C VIRUS AND KINASES ........................................... 15 
 vi 
1.2.2.3 DEVELOPMENT OF THE MYRISTOYLATED HUMAN 
KINASE LIBRARY........................................................................................... 16 
1.2.2.4 RELEVANCE...................................................................................... 17 
1.3 SUMMARY ........................................................................................................ 18 
2.0 OBJECTIVE ............................................................................................................... 19 
2.1 SPECIFIC AIM 1: TO IDENTIFY HUMAN KINASES THAT INHIBIT 
HCV INFECTION THROUGH GENOMIC SCREENING .......................................... 20 
2.2 SPECIFIC AIM 2: TO DETERMINE THE STAGE OF VIRAL LIFE 
CYCLE AT WHICH KINASES ACT UPON HCV INFECTION ............................... 23 
2.3 SPECIFIC AIM 3: TO INVESTIGATE THE MOLECULAR MECHNISMS 
BY WHICH KINASES INHIBIT HCV INFECTION ................................................... 24 
3.0 MATERIALS AND METHODS ............................................................................. 25 
3.1 MYRISTOYLATED KINASE LIBRARY ..................................................... 25 
3.2 KINASE PLASMIDS ....................................................................................... 25 
3.3 CELL CULTURE ............................................................................................. 26 
3.4 LENTIVIRAL PACKAGING SYSTEM ........................................................ 26 
3.5 VIRUS INFECTION ........................................................................................ 27 
3.6 CELL VIABILITY ASSAY ............................................................................. 27 
3.7 IMMUNOFLUORESCENT STAINING........................................................ 28 
3.8 PSEUDOPARTICLE PACKAGING SYSTEM ............................................ 28 
3.9 RNA ISOLATION ............................................................................................ 29 
3.10 REAL-TIME RT-PCR ..................................................................................... 29 
3.11 DETERMINATION OF INTERFERON PRODUCTION ........................... 30 
 vii 
3.12 NDV-GFP BIOASSAY ................................................................................... 30 
3.13 CELL CYCLE ANALYSIS ........................................................................... 31 
3.14 WESTERN BLOTTING ................................................................................ 31 
3.15 CLONING AND SEQUENCING .................................................................. 31 
3.16 PCR .................................................................................................................. 32 
4.0 RESULTS ................................................................................................................ 33 
4.1 PRIMARY SCREENING OF KINASE LIBRARY .................................... 33 
4.2 SECONDARY SCREENING OF KINASE LIBRARY .............................. 36 
4.3 VALIDATION OF SCREENED KINASES BY IMMUNOSTAINING OF 
HCV PROTEINS ............................................................................................................. 40 
4.4 DETERMINATION OF WHETHER KINASE AFFECTS VIRAL ENTRY 
BY HIV-HCV PSEUDOPARTICLES (HCVPP) ........................................................... 43 
4.5 DETERMINATION OF WHETHER KINASE AFFECTS VIRAL 
REPLICAITON BY RT-PCR ........................................................................................ 44 
4.6 DETERMINE THE POTENTIAL ACTIVATION OF INTERFERON 
PRODUCTION ................................................................................................................ 46 
4.7 DETERMINATION OF NDV-GFP BIOASSAY ........................................ 47 
4.8 DETERMINATION OF WHETHER KINASES ALTER CELL CYCLE
 ………………………………………………………………………….......... 48 
4.9 LOCALIZATION PATTERN OF ACTIVATED KINASES.................... 50 
4.10 MAP2K5 SURROUNDS LIPID DROPLETS............................................. 53 
5.0 DISCUSSION ......................................................................................................... 57 
6.0 FUTURE DIRECTIONS ....................................................................................... 61 
 viii 
7.0 PUBLIC HEALTH RELEVANCE .................................................................... 62 
BIBLIOGRAPHY ................................................................................................................. 63 
 ix 
LIST OF TABLES 
 
Table 1. Summary of all kinases included in the cDNA library ................................................... 21 
Table 2. Forward and reverse primers of kinases used for PCR ................................................... 32 
 x 
LIST OF FIGURES 
 
Figure 1. The HCV genome ............................................................................................................ 4 
Figure 2. The HCV lifecycle ........................................................................................................... 5 
Figure 3. Myristoylation overview ............................................................................................... 14 
Figure 4. Categorizations of 192 human kinases .......................................................................... 22 
Figure 5. Principle of the cell viability assay ................................................................................ 27 
Figure 6. Initial screening of the myristoylated kinase library ..................................................... 54 
Figure 7. Transient expression of kinases did not alter cell viability ........................................... 36 
Figure 8. CKS1B, MAP2K5 and PACSIN1 inhibited HCVcc infection ...................................... 38 
Figure 9. Individual kinases in pool 7 resulted in no significant effects upon HCVcc infection . 39 
Figure 10. Kinases exhibited significant inhibitory effects against HCVcc infection in Huh 7.5.1 
cells ............................................................................................................................................... 40 
Figure 11. Kinases did not exhibit effects upon Dengue infection ............................................... 42 
Figure 12. Identified kinases did not inhibit HCV entry .............................................................. 43 
Figure 13. CKS1B and MAP2K5 supressed HCV RNA replication ............................................ 45 
Figure 14. Expression of kinases did not induce transcription from IFN or ISG promoters ........ 47 
Figure 15. Kinase expression did not suppress NDV infection .................................................... 48 
Figure 16. Kinase expression did not alter cell cycle ................................................................... 49 
 xi 
Figure 17. Expressions of Flag-tagged kinases in 293T cells ....................................................... 51 
Figure 18. Cellular distribution of kinases .................................................................................... 52 
Figure 19. Localization of kinases with respect to lipid droplet ................................................... 53 
Figure 20. MAP2K5 surrounds lipid droplet ................................................................................ 54 
Figure 21. PACSIN1 decreases the level of p7…………………………………………………61 
 
 xii 
                                              ACKNOWLEDGEMENTS 
I would like to sincerely thank my advisor Dr. Tianyi Wang, in which this project would not 
have been possible without his guidance, patience, encouragement and his extended valuable 
assistance and advice, he has been my inspiration as I stumbled across many challenges during 
the completion of this research work. In truth, my successes are reflections of him and I continue 
to admire his leadership, creativity and dedication in this research field. He has been the most 
knowledgeable source who has always been a good listener and his willingness to devote his 
time in training me was exceptional. I am truly grateful for given the opportunity to grow as a 
scientist under his guidance, mentorship and continuous support. I would also like to thank Dr. 
Todd Reinhart, Dr. Sluis-Cremer and Dr. Velpandi Ayyavoo, for supporting my thesis project 
and providing valuable suggestions in regards to my project.     
 
          I extend my thanks to my fellow lab members Shufeng Liu and Derek Rinchuse for their 
support and friendship. They have been my mental support, great friends and as fellow scientists, 
they made our laboratory a wonderful work environment.   
 
“If I have seen a little further than others,  
it is by standing upon the shoulders of Giants” 
- Isaac Newton  
 xiii 
1.0  INTRODUCTION 
 
1.1 HEPATITIS C VIRUS 
 
1.1.1 HEPATITIS C VIRUS BURDEN AND DISEASE 
Hepatitis C virus (HCV) affects approximately 170 million people worldwide and is a major 
cause of liver diseases. The World Health Organization estimates that the virus infects 3% of the 
global population and that 3-4 million new infections occur annually [1, 2]. HCV is remarkable 
in that it has the ability to establish persistent infections and has poor treatment response to 
prevalent HCV genotypes [3-5]. The majority of HCV infections are chronic with at least 70% of 
acute infections progressing to persistence, associated with chronic acute hepatitis, cirrhosis, and 
hepatocellular carcinoma [6, 7]. HCV is primarily transmitted through direct blood contact, 
although most infections go unrecognized due to mild disease symptoms [3-5].  
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          HCV replicates rapidly in untreated patients, producing about one trillion virus particles 
per day [8]. HCV is diverse genetically with six major genotypes and each is subcategorized into 
several subtypes and many strains. Genotype 1 viruses cause the majority of all infections, 
predominating in North America, South America and Europe, and genotype 2 viruses are less 
common throughout the world [9]. Genotype 3 viruses predominate in Southeast Asia and 
Russia, while genotype 4 viruses predominate in the Middle East, Egypt and central Africa. 
Genotype 5 viruses are responsible for most infections occurring in South Africa and genotype 6 
viruses are endemic to Asia [9].  
 
          Standard treatment is a combination therapy of polyethylene glycol-conjugated interferon-
alpha and ribavirin [10]. Although this combination therapy elicits a strong synergistic inhibitory 
effect on subgenomic HCV replication, patients are expected to endure severe side effects such 
as flu-like symptoms, depression and anemia, that often result in poor patient compliance [11, 
12]. Also, the high cost of these antiviral drugs prohibit many clinicians from offering treatment 
to patients who lack the social and financial support necessary for such therapy with strict 
adherence [11, 12]. The recent approval of two HCV protease inhibitors, Merck’s boceprevir and 
Vertex’s teleprevir, in May 2011 by the Food and Drug Administration (FDA) highlighted the 
success of developing small molecule inhibitors to treat chronic HCV infection [13]. Resistance 
to these inhibitors, however, is expected to emerge rapidly in clinics. As with HIV treatment, a 
successful treatment of HCV is expected to involve combination therapy with multiple inhibitors 
of different target. Currently, neither a prophylactic nor a therapeutic vaccine is available and 
their development has been hampered by the high variability of the virus. 
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1.1.2 HCV GENOME 
HCV is an enveloped, positive-stranded RNA virus classified in the hepacivirus genus within the 
Flaviviridae family [14]. The size of its genome is approximately 9.6 kb and consists of a 5’ 
non-translated region (NTR) that functions as an internal ribosome entry site, a long open 
reading frame (ORF) encoding a precursor polyprotein of approximately 3000 amino acids and a 
3’ NTR. The translation of HCV polyprotein is mediated by the internal ribosomal entry site 
within the 5’ NTR. As shown in figure 1, the HCV polyprotein is cleaved by host peptidases and 
viral proteases, both co- and posttranslationally to yield a total of ten viral proteins, that includes 
a core protein, E1 and E2 (envelope glycoproteins), p7 (short hydrophobic peptide), which are 
structural proteins, and a number of nonstructural proteins such as NS2, NS3, NS4A, NS4B, 
NS5A and NS5B. Studies have shown that NS3 to NS5B proteins are sufficient for HCV RNA 
replication, which occurs in the membrane-bound replication complex consisting of HCV RNA 
and proteins [14]. The core and NS5B coding regions also contain cis-acting RNA elements 
important for HCV RNA replication and regulation. Lastly, the newly synthesized HCV proteins 
and genomic RNA are packaged into progeny virus particles, although the molecular aspects of 
underlying HCV virion assembly, maturation and egression are not well understood [15].    
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 Figure 1. The HCV genome. The HCV genome is approximately 9400bp, which is translated as a single 
polypeptide that is cleaved to produce 10 mature proteins. Core-E1, E1-E2, E2-p7 and p7-non-structural protein 2 
(NS2) junctions are cleaved by cellular peptidases to yield structural proteins. NS3 serine protease cleaves the 
remainder of the NS polypeptide.  
 
 
1.1.3 HCV LIFE CYCLE 
The positive-sense HCV genome is packaged in an icosahedral scaffold of Core proteins, which 
are enveloped by phospholipid membranes derived from the host cell endoplasmic reticulum [16, 
17]. The viral envelope glycoproteins E1 and E2 mediate fusion to the host cell membrane 
receptors Tetraspanin (CD81) and Scavenger receptor class B type I (SR-B1) [16, 17]. 
Additional factors necessary for efficient HCV entry are Claudin 1, Occludin, Low-density 
lipoprotein receptors and glycosaminoglycans [16-21]. After receptor-mediated entry, the virus 
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enters cytosol of the host cell by clathrin-mediated endocytosis, and next the fusion to the 
endosomal membrane is mediated by the acidic endoplasmic environment that lead to the release 
of the RNA genome into the cytoplasm [17, 22]. HCV genome is then translated by host cell 
machinery and the structural proteins are inserted into the endoplasmic reticulum lumen and 
cleaved into functional units by host peptidases [2, 23]. The non-structural proteins are translated 
on the cytoplasmic side of the endoplasmic reticulum and processed into functional units by viral 
proteases NS2/3 and NS3/4A. The viral RNA-dependent RNA polymerase, NS5B, initiates HCV 
replication by synthesizing a single, negative-sense strand from the positive-sense RNA genome 
[23-25]. Finally, the HCV genomes will enter the endoplasmic reticulum and packaged into virus 
particles, that are trafficked through the Golgi secretory pathway for extracellular release [23-
26].    
 
Figure 2. The HCV lifecycle.  HCV virions attach to human hepatocytes by binding to various surface molecules 
including HSPG (heparin sulfate proteoglycans), CD81 and SR-B1 (scavenger receptor class B type 1), and enter by 
clathrin-mediated endocytosis; virus particles uncoat in the cytosol and host cell machinery translates the genomic 
RNA along the endoplasmic reticulum membrane; virus replicates and new virions assemble in the endoplasmic 
reticulum and trafficked through the Golgi secretory pathway for release. Reprinted from Nature Reviews 
Gastroenterology & Hepatology 6, 403-411 (July 2009), with permission from Nature Publishing Group.    
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1.1.4 HCV ASSEMBLY AND LIPID DROPLETS 
HCV particles can be found in low-density fractions of plasma from infected patients. Thomssen 
and colleagues first demonstrated an association of HCV particles β-lipoproteins [27]. 
Accumulated evidence now indicate HCV exist as so-called “lipoviroparticles’ (LVPs) in vivo, 
which are rich triglycerides and contain at least apolipoprotein B (ApoB), HCV RNA and the 
viral core protein at densities of <1.08 g/ml [28, 29].  By contrast, laboratory-grown HCVcc 
(HCV propagated in cell culture) particles display a slightly higher density (∼1.15 g/ml) [30, 31] 
due to the association with ApoE and ApoCI, and are mostly devoid of ApoB [32-34]. The 
presence of apolipoproteins significantly influences the viral infectivity as antibodies against 
ApoE potently neutralized the virus [35]. Moreover, the lipoprotein secretion pathway plays a 
critical role in the assembly and release of infectious HCV lipoviroparticles [36].  
 
          Relevant to my thesis, chronic HCV infection is previously known to induce accumulation 
of lipids in the liver (steatosis). Recent studies have suggested that cellular lipid droplets (LDs) 
also play a crucial role in the HCV life cycle (reviewed in [29])[37].  Originated from the ER, 
LDs are cellular organelles storing lipids. The core of LDs is formed by triglycerides and 
cholesterol esters, which is then surrounded by a phospholipid monolayer and a host of proteins 
at their surface.  Interactions between HCV core protein and LDs are required for the 
morphogenesis of infectious HCV.  Miyanari et al. elegantly demonstrated that HCV Core 
recruits nonstructural (NS) proteins and replication complexes to LD-associated membranes, and 
that this recruitment is critical for producing infectious viruses. In that study, virus particles were 
observed in close proximity to LDs, indicating that some steps of virus assembly take place 
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around LDs [38]. It is now postulated that cytosolic LDs serve as the platforms for virus 
assembly by first recruiting viral Core protein to its surface. The viral NS5A also localizes to 
LDs, and the colocalization of Core and NS5A is crucial to the assembly of infectious virus via a 
yet-to-be-defined mechanism. 
1.1.5 CELL LINES TO STUDY HCV 
The hepatocyte is the primary target cell in HCV infection, although various lymphoid 
populations such as B cells and dendritic cells have been reported to be capable of being infected 
at very low levels [39, 40]. In the past, the HCV life cycle and host-virus interactions have been 
difficult to study due to lack of cell culture and small animal model availability. Thus, the 
majority of the HCV infection studies in the beginning revolved around infected patients and 
chimpanzees [41]. This difficulty was overcome by various developments of cell lines and other 
methods to study HCV life cycle. The development of HCV replicon systems, for example, have 
helped with the study of HCV translation and RNA replication in human hepatoma-derived Huh-
7 cells in vitro [42].  By definition, a replicon is a nucleic acid (can be either DNA or RNA) that 
is capable of autonomous replication. The advantage of using this system is that it allows 
assessment of HCV replication. The study of HCV entry, on the other hand, became possible by 
the use of pseudoviruses that mimic HCV entry [43, 44]. It was reported that retroviral construct 
carrying reporter genes can be pseudotyped with HCV E1 and E2 and produce infectious viral 
particles [43]. These pseudoviral particles strictly infect primary human hepatocytes or a human 
liver cell line Huh7 in E1E2-dependent manner. Another major breakthrough in the field came in 
2005 by Wakita and colleagues who demonstrated that a HCV isolate named Japanese fulminant 
hepatitis 1 (JFH1) propagated efficiently in cell culture and produced infectious particles [45]. 
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To date, intragenotypic and intergenotypic constructs carrying reporter genes were developed to 
allow study of entire HCV life cycle in cell culture system (HCVcc) [46, 47].    
1.1.5.1     CELL LINES PERMISSIVE FOR HCV REPLICATION 
 
Productive replication of HCV replicons in vitro is extremely cell-type specific, with human 
hepatoma Huh-7 cells being the most permissive cell line identified so far [46]. The development 
of these cell lines was made possible after observing that structural proteins are not required for 
the replication of many positive-sense RNA viruses. The first generation functional HCV 
replicons were derived from the Con 1 cDNA that was isolated from the liver of a chronically 
infected patient with genotype 1b strain [48-50]. Efforts to find other permissive cell lines have 
been devoted in the past and still continue today. The non-hepatic cell lines identified in the past 
include human cervical cancer-derived HeLa cell line and 293 cells established from human 
embryonic kidney. 
 
          A subclone derived from Huh 7 is the Huh 7.5, with the capacity to support high levels of 
subgenomic HCV replication in approximately 75% or higher transfected cells [51]. Huh 7.5 
cells more readily support RNAs with lower replicative abilities, such as full-length Con1 
replicons [51]. This increased permissiveness of Huh 7.5 cells is due to mutational inactivation 
of the retinoic acid inducible gene-I (RIG-I), a cytoplasmic protein that recognizes structured 
RNA to induce type I IFN production via activation of transcription factors interferon regulatory 




1.1.5.2       DEVELOPMENT OF HCV REPLICONS 
 
In the past, numerous attempts have been made to propagate HCV in cell culture by infection 
with virus containing inoculum, but the replication levels were often transient and always so low 
that HCV RNA synthesis could not be monitored by reverse transcription (RT)-PCR assays, 
complicating detailed studies of HCV replication [48-50, 53]. For most positive-sense RNA 
viruses, productive replication can be efficiently made by transfecting permissive cells with the 
genomic RNAs, allowing to bypass viral entry and uncoating steps. However, transfection of 
HCV RNAs transcribed from cDNA clones with known infectivity still never effectively 
established HCV replication [48-50, 53-55]. Thus great efforts were made to generate replicons 
and it was noted that even the slightest variation in HCV sequence could drastically change the 
ability of engineered replicons. 
 
          For many years, the only HCV replicons able to replicate in cultured Huh-7 cells were 
derived from Con1 strain. However, this restriction has overcome by the development of 
replication-competent subgenomic RNAs derived from independent genotype 1b isolates. Unlike 
the Con1 replicons, HCV genotype 1b does not require cell culture adaptation for efficient 
replication of subgenomes derived from HCV-N isolate, or for the G418 selection of Huh-7 
clones [56, 57].  
 
          Another genotype was derived from clone H77, known as HCV genotype 1a, in which 
intrahepatic inoculation of H77 RNA results in high viremia in the chimpanzee [58]. However, 
replicons derived from this infectious H77 clone require at least two adaptive mutations to 
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productively replicate in cell culture [41, 59]. Transfection of H77 clones with single adaptive 
mutation S2204I in NS5A into permissive Huh-7 or Huh-7.5 subline allowed for the 
establishment of the first G418-resistant colonies supporting H77 replication [41, 59, 60].    
 
          Finally, genotype 2a is a subgenomic replicon derived from the genotype 2a JFH-1 clone 
that was isolated from a patient with fulminant hepatitis, and represents the only non-genotype 1 
sequence capable of replication in cell culture. The JFH-1 subgenomes replicate with high 
efficiency in permissive cell lines without any adaptive mutations. So far, the JFH-1 subgenomic 
RNA is the most efficient replicon tested [61, 62].   
1.2 KINOME 
Kinome is defined as the protein kinase complement of the human genome [7]. This term was 
coined in 2002 by Gerard Manning and colleagues when they identified 518 putative human 
protein kinase genes and the evolution of protein kinases were analyzed [63]. Ever since the 
discovery that reversible phosphorylation regulates the activity of glycogen phosphorylase, there 
has been a great interest in the role of protein phosphorylation in regulating protein function [63]. 
The advancement of DNA cloning and sequencing in the mid-1970s made it possible to confirm 
the existence of protein kinases. Such near-completion of the human genome sequence now 
allows the identification of almost all human protein kinases [63]. To date there are 
approximately 500-600 known kinases and open reading frames (ORFs) that are important in 
regulating cellular processes. Many studies involving proteomics require cloning and 
manipulation of these large numbers of protein-encoding sequences, or open reading frames [7].  
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          The ORFeome of an organism corresponds to its complete set of protein-encoding genes, 
cloned as full-length open reading frames (ORFs) [7]. An open reading frame consists of the 
entire coding sequence between the initiation and termination codons, excluding the 5’ and 3’ 
mRNA untranslated regions [7].  
1.2.1 CLASSIFICATION OF THE HUMAN KINOME 
The protein kinases are related by their homologous kinase domains, also known as catalytic 
domains which consists of approximately 200-300 amino acid residues [63, 64]. These kinase 
domains are what impact their specific kinase activity. There are three key roles that these kinase 
domains play: 1) binding and orientation of the ATP phosphate donor as a complex with divalent 
cation (usually Mg2+ or Mn2+); 2) binding and orientation of the protein substrate; and 3) transfer 
of the γ-phosphate from ATP to the acceptor hydroxyl residue (serine, threonine or tyrosine) of 
the protein substrate [64]. The kinase domains can be further divided into 12 smaller 
subdomains, defined as regions never interrupted by large amino acid insertions and containing 
characteristic patterns of conserved residues [64].  
 
          Kinases are primarily classified by sequence comparison of their catalytic domains, aided 
by the knowledge of sequence similarity and domain structure outside of the catalytic domains, 
and known biological functions [64]. The original classification of kinases is the Hanks and 
Hunter human kinase classification system that divides the kinases into four broad groups, 44 
families and 51 subfamilies [64]. The Hanks and Hunter human kinase classification system 
basically subdivided the known members of the eukaryotic protein kinase superfamily into 
distinct families that share basic structural and functional properties, where phylogenetic trees 
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derived from an alignment of kinase domain amino acid sequences served as the basis for this 
classification system [64]. The major four groups include: 1) the AGC group, which includes the 
cyclic-nucleotide-dependent family (PKA and PKG), the protein kinase C (PKC) family, the 
beta-adrenergic receptor kinase (βARK) family, the ribosomal S6 kinase family, and other close 
relatives; 2) the CaMK group, which includes the family of protein kinases regulated by 
calcium/calmodulin, the Snf1/AMPK family, and other close relatives; 3) the CMGC group, 
which includes the family of cyclin-dependent kinases, the Erk (MAP) kinase family, the 
glycogen synthase 3 (GSK3) family, the casein kinase II family, the Clk (Cdk-like kinase) 
family, and other close relatives; and 4) the protein-tyrosine kinase (PTK) group [64].  
 
          The AGC group of protein kinases is comprised of mostly basic amino acid-directed 
enzymes, phosphorylating substrates at Ser/Thr residues. The CaMK group of protein kinases 
also tends to be basic amino acid-directed and as one can predict the AGC and CaMK groups fall 
near one another in the phylogenetic tree [64]. Within this group is the Erk (MAP) kinase family, 
in which for the most part, they are proline-directed enzymes, phosphorylating substrates at sites 
lying in Pro-rich environments [64]. The protein-tyrosine kinase group consists of a quite large 
number of enzymes, whose kinase domains specifically phosphorylate on Tyr residues. These 
major groups are distinct from those kinases that are able to phosphorylate with dual-specificity 
such as those able to phosphorylate a substrate on Ser/Thr and Tyr, which are members of the 
MEK family [64].  
 
          Since then, Gerard Manning and colleagues have added four new groups, STE group that 
consists of MAPK cascade families, the CK1 group that consists of CK1, TTBK (tau tubulin 
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kinase) and VRK (vaccinia-related kinase) families, TKL (tyrosine kinase-like) group that 
consists of families that resemble both tyrosine and serine-threonine kinases, and finally RGC 
(receptor guanylate cyclase) group that are similar in domain sequence to tyrosine kinases [63].  
1.2.2 KINASES    
Protein kinases are one of the largest protein superfamilies identified largely from eukaryotic 
sources [63, 64]. These enzymes use the γ-phosphate of adenosine triphosphate (ATP) to 
generate phosphate monoesters using protein alcohol groups on Serine (Ser) and Threonine (Thr) 
residues, and protein phenolic groups on Tyrosine (Tyr) as phosphate acceptors [64].  The 
protein kinases comprise a large group of enzymes that mostly catalyze the covalent attachment 
of a phosphate group to a protein, and in eukaryotic cells, protein kinases mediate most of the 
signal transduction by modification of substrate activity and control cellular processes including 
but not limited to metabolism, transcription, cell cycle progression, cell movement, apoptosis, 
differentiation, and protein phosphorylation [63]. However, most protein kinases act in a network 
of kinases and other signaling effectors, not just working independently by themselves.   
1.2.2.1      MYRISTOYLATION 
 
Myristoylation refers to the irreversible covalent linkage of the 14-carbon saturated fatty acid, 
myristic acid, to the N-terminalglycine of many eukaryotic and viral proteins through a stable 
amide bond [65]. This reaction is catalyzed by myristoyl-CoA:protein N-myristoyltransferase 
(NMT) [65-67]. Historically, N-myristoylation was first described as an unusual blocking group, 
which prevented the direct use of Edman degradation at the N-terminus of the catalytic subunit 
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of cyclic AMP-dependent protein kinase and calcineurin B [68, 69]. It was later identified by 
mass spectrometry that this blocking group is myristic acid. N-myristoylation was first described 
as a co-translational modification that occurs on a nascent polypeptide following the removal of 
the initiator methionine residue [70, 71]. Now it is accepted that myristoylation can also occur 
post-translationally on an internal glycine within a cryptic myristoylation consensus sequence 
exposed by the action of caspases in apoptotic cells [65, 72-75]. The removal of the initiator 
methionine is a common modification of many protein, occurring in approximately 80% of total 
proteins, but only selected proteins are specifically myristoylated due to the selectivity of NMTs 
[65]. This selectivity is partly explained by the 3D structure of NMT, in which the bent active 
site cavity is only large enough to selectively accommodate a myristoyl functional group [65, 
76]. The general consensus peptide sequence recognized by NMTs is Gly-X3-X4-X5-
(Ser/Thr/Cys)6 where X represents most amino acids, except for proline, aromatic or charged 
residues in position X3 [65]. It is also noted that Ser, Thr, Cys are preferred at position X6 
although other amino acids can be tolerated occasionally [65].   
 
 
Figure 3. Myristoylation overview. Myristoylation consists of the covalent addition of 14-carbon saturated fatty 
acid myristate to the N-terminal glycine residue through a stable amide bond. The reaction is catalyzed by the 
enzyme myristoyl-CoA:protein N-myristoyl-transferase. 
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          Myristoylation has been shown to be important in mediating subcellular targeting, protein-
protein and protein-membrane interactions required for the activities of many proteins and is 
often required for membrane binding [77]. Myristoylation is also involved in differential 
targeting to membranes and sub-membrane domains known as lipid rafts [65, 78]. Myristoylation 
is thus important in a variety of cellular functions such as many signaling pathways, oncogenesis 
and viral replication [65]. The importance of myristoylation in viruses has been studied in the 
field of HIV-1. Nearly all mammalian retroviral Gag proteins are myristoylated and the Gag 
protein has been reported to be post-translationally modified with an N-terminal myristate group 
which targets Gag to lipid rafts, aiding in assembly [79, 80]. In HIV-1, the membrane binding 
domain maps to the N-terminal region of p17 matrix (MA), and it is known that for the 
membrane binding domain to function, it has to be covalently modified at the N terminus by 
myristate and this importance is noted by the fact that almost all mammalian retroviral Gag 
proteins are myristoylated [79]. This lipid modification of proteins plays many roles inside and 
outside of the cell including directing proteins to various cellular membranes, sub-membrane 
domains and promoting protein-protein interactions. Thus, one can view protein lipidation as 
adding another level of function in many proteins involved in cellular processes. Specifically in 
relation to kinases, myristoylation is often required for their membrane recruitment and 
activation. Previous studies for example illustrated this by showing that the addition of a 
myristoylation sequence activates both the PI3K p110α subunit and AKT [81-86].  
1.2.2.2     HEPATITIS C VIRUS AND KINASES 
 
As kinases can be the targets for drugs and a control point for numerous cell behaviors, the 
kinome has recently been used for large-scale functional genomics with RNAi screens. One 
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recent report by Reiss and colleagues showed a screening of siRNA library targeting all known 
and predicted 719 human kinases and identified phosphatidylinositol-4 kinase III alpha 
(PI4KIIIα) to be important in HCV entry and replication [87]. In this particular study, it was 
reported that the nonstructural HCV protein NS5A binds to and activates PI4KIIIα, and this 
kinase seemed to localize primarily at the endoplasmic reticulum (ER), which is thought to be 
the origin of HCV replication sites [87]. This kinase was previously confirmed by another group, 
in which they used an siRNA library targeting 140 cellular membrane-trafficking genes and 
systematically evaluating their impact on the production of infectious HCV and HCV 
subgenomic replicon replication [88]. HCV infections in particular have been linked to host 
kinases in the past, and other kinases reported to be important in HCV replication include casein 
kinases I and II, and choline kinase alpha (CHKA) [89, 90]. Other kinases that have been 
reported to target NS5A also include AKT, p70s6K, MEK, MKKI and CKII [91]. The casein 
kinase II (CKII) in particular has been implicated as a NS5A directed kinase important for HCV 
particle assembly [92].   
1.2.2.3        DEVELOPMENT OF THE MYRISTOYLATED HUMAN KINASE LIBRARY 
 
In this thesis project, 192 myristoylated human kinases were purchased from Addgene. Therefore 
it is important to understand how and why this library was created. In 2007, Boehm and 
colleagues tried to manipulate normal cells into cancer cells by activating and inactivating 
different kinase pathways [6]. One could easily do this by predicting which genes are involved 
and test them, but Boehm and colleagues wanted to do this in the most unbiased way possible to 
look for novel oncogenes and tumor suppressor genes. Thus, Boehm and colleagues approached 
this issue by using cDNA libraries, but with such high order of complexity generated by cDNA 
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libraries, it was difficult to find true candidates in such complex collections of molecules for 
overexpression. This led to the use of overexpression clones that expresses kinases genes one by 
one, and allowed this group to identify new breast cancer oncogene [6, 93]. The original Center 
for Cancer Systems Biology (Dana Farber Cancer Institute)-Broad Human ORF collection 
(CCSB Broad Kinase Library) from Addgene consists of 559 distinct human kinases and kinase-
related protein ORFs in pDONR-223 Gateway Entry vectors, and all clones are clonal isolates 
that have been end-read sequenced to confirm identity [93]. The kinase ORFs were assembled 
from various sources: 56% were isolated as single cloned isolates from the ORFeome 5.1 
collection; 31% were cloned from normal human tissue RNA (Ambion) by reverse transcription 
and subsequent PCR amplification adding Gateway sequences; 11% were cloned into Entry 
vectors from templates obtained from collaborating laboratories, and all ORFs are open (stop 
codons removed) except for 5 (MST1R, PTK7, JAK3, AXL, TIE1) which are closed 
(www.addgene.org/human-kinase/).  
1.2.2.4        RELEVANCE 
 
Hepatitis C virus continues to be a significant threat to public health worldwide, despite 
continuous efforts to develop effective treatments and understanding the pathogenesis as well as 
further enhancing our understanding of the virus itself. The current treatment of HCV infected 
patients is not highly effective in all cases and produces severe side effects that cause patients to 
be unwilling to take further drug treatments. The research in kinases in relation to HCV is 
relatively new and although there have been reports that link between host kinases and HCV 
infection, anti-viral activity of the kinases to HCV has not been reported nor identified. Thus, 
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upon identification of such kinase-mediated anti-HCV pathways, these novel kinases could 
potentially act as novel compounds as means to combat HCV infection.  
1.3 SUMMARY 
The human kinome includes between 500-600 known kinases and open reading frames (ORFs) 
that play key roles in regulating many cellular processes. Some of these cellular processes 
include, signal transduction, metabolism, transcription, cell cycle progression, cell movement, 
apoptosis, differentiation and protein phosphorylation. Various protein and lipid kinases have 
previously been shown to control HCV life cycles in several genomic screens using small 
interference RNAs that target human kinases.  In this study, the goal was to identify kinases 
whose activities limit HCV infection using a gain-of-function approach and to perform initial 
validation and characterization of kinase-mediated HCV inhibition. The detailed molecular 
mechanisms will be investigated in depth in the future.  
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2.0  OBJECTIVE 
HCV infection is a leading cause of liver diseases worldwide and due to its persistence, HCV-
related pathologies are expected to rise in the future [94]. The combination therapy not only 
causes severe side effects, but the unavailability of vaccine or alternative treatments calls for 
attention. In the past, several kinases that are required for HCV infection were identified through 
siRNA or chemical inhibitor screenings [87, 95-100]. The objective of this study was to screen 
for additional human kinases that may suppress or promote HCV infection through a gain-
of-function approach. Selected kinases were further characterized in terms of their 








2.1 SPECIFIC AIM 1: TO IDENTIFY HUMAN KINASES THAT INHIBIT HCV 
INFECTION THROUGH GENOMIC SCREENING 
 
Previous studies have identified several kinases involved with HCV entry and replication by 
siRNA screening or chemical inhibitor based methods, which adopt loss-of-function approach. In 
my study, an overexpression of the kinases is used for gain-of-function approach to perform 
primary screening in our 192 human myristoylated kinase library (Table 1) (all plasmids can be 
found at http://www.addgene.org/MKL/). In this primary screening, the kinases were grouped in 
pools containing eight kinases to make the screening more manageable in the given time frame. 
This primary screening led to secondary screening, where the selected pool of kinases considered 
being significant was individually screened to identify the exact kinase of interest. Validation of 
the selected kinases was performed to confirm the significance of the identified kinase. This 























Figure 4. Categorizations of 192 human kinases. 192 human kinases are categorized according to their annotated 
cellular localizations, involvement in biological processes and molecular functions. The numbers included in the 
figure indicates the number of kinases that fall into each category. Of note, some kinases are classified into more 





2.2 SPECIFIC AIM 2: TO DETERMINE THE STAGE OF VIRAL LIFE CYCLE AT 
WHICH KINASES ACT UPON HCV INFECTION 
The identified kinases of interest at this point have been individually selected out from the 
original kinase library. The selected kinases could be involved in any step of the viral life cycle, 
such as entry, replication and assembly/release. In order to pinpoint exactly which step of the 
viral life cycle the kinase is responsible for the inhibition of HCV infection, each step must be 
investigated. The replication step of the viral life cycle can be determined by RT-PCR. The viral 
entry can be studied by using pseudoviruses that mimic HCV entry and a cell culture system that 
supports production of infectious HCV. In this study, HCVpp and VSV-Gpp were used as 
lentiviral particles pseudotyped with HCV E1 and E2 glycoproteins and VSV-G glycoproteins 
respectively to study viral entry. To assess the effect of kinases on viral replication, a replicon 
cell line harboring the full-length genome of the HCV genotype 1b (2-3+) was maintained in cell 
culture in the presence of various kinases. The viral RNA (vRNA) level was evaluated by real-








2.3 SPECIFIC AIM 3: TO INVESTIGATE THE MOLECULAR MECHNISMS BY 
WHICH KINASES INHIBIT HCV INFECTION 
There are several ways for a kinase to inhibit HCV infection: (1) kinases-mediated pathways 
may activate the production of interferons, which are known inhibitors of viral infection. (2) 
Kinase expressions may alter cell cycle and HCV replication is prone to the changes of cell 
cycle. (3) HCV NS5A is a known target for serine-threonine phosphorylation. Although the 
importance of NS5A phosphorylation remains controversial, there were studies showing that 
hyperphosphorylation of NS5A decreased virus replication [101]. Hence identified kinases may 
hyperphosphorylate NS5A. (4) Other possible mechanisms include but are not limited to: 
disruption of the formation of viral replication complex, interference of viral assembly and 
release. The first three possibilities were investigated in detail as part of my thesis study and then 
the possible association of kinases with lipid droplet, the important cellular organelle where virus 
assembly occurs, was examined by confocal microscopy.  
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3.0  MATERIALS AND METHODS 
 
3.1 MYRISTOYLATED KINASE LIBRARY 
The kinase library consisting of 192 human myristoylated kinases was purchased from Addgene. 
These kinases were shipped as glycerol stock in two 96-well plates, namely referred to as plates 
1 and 2. These kinases contain kinase-related open reading frames (ORFs) cloned into a 
retroviral vector which adds a myristoylation sequence and flag-epitope tag to each ORF. The 
plates were stored in -80° C.   
3.2 KINASE PLASMIDS 
Each individual kinase glycerol stock was inoculated in 3 ml of Luria broth (LB) with ampicillin 
and incubated overnight at 37° C with vigorous shaking. The DNA was isolated next day using 
Plasmid Mini Kit I (Omega, bio-tek), and the isolated DNA was subjected to optical density 
(O.D) reading. DNA isolation was repeated until the concentration and purity ratio were optimal.   
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3.3 CELL CULTURE 
HCV permissive cell line Huh 7.5.1 was used with the passage number between 1-10 at all times. 
The cells were maintained in complete growth medium DMEM - Dulbecco’s modified Eagle 
medium (Cellgro® Mediatech) supplemented with 10% heat inactivated Fetal Bovine Serum 
(FBS), 100 U penicillin/0.1 mg/ml streptomycin/2mM glutamine and 0.1 mM nonessential 
amino acids at 37° C and 5% CO2.  
3.4 LENTIVIRAL PACKAGING SYSTEM 
To perform primary screening, lentiviral packaging system was used. This involves three 
plasmids, eight kinase DNA, MLV-gag-pol and VSV-G packaged in 293T Lenti-X cell line. The 
kinases were pooled in groups of eight in the primary screening to make the screening 
manageable in the given time frame. The plasmids were transfected using 1µg/µl of 
polyethylenimine (PEI) and after 72-hours, the supernatant containing the packaged virus was 
collected and stored in -80° C freezer. The virus was also harvested twice every 12 hours for a 
total of three collection times.  
 
          In the secondary screening, the same method was applied, except the kinases in each pool 
were individually packaged.   
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3.5 VIRUS INFECTION 
The virus collected from packaging was used to infect Huh 7.5.1 cells, incubated with the cells in 
the presence of 4 µg/ml polybrene at 37° C for 3-6 hours prior to removal of virus. The cells 
were gently washed once with pre-warmed complete media to remove residual virus.    
3.6 CELL VIABILITY ASSAY 
To rule out the possibility of the contribution of altered cell viability by expressing active 
kinases, cellular ATP levels was measured. The cellular ATP levels reflect the cell viability and 
metabolism, made possible by using Cell Titer Glo luciferase kit to be detected in luminometer 
(Figure 5).  
 
 
Figure 5. Principle of the cell viability assay. To determine cell viability, cellular ATP levels are measured, in 
which the luminescence produced by the cells is proportional to the number of viable cells.  
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3.7 IMMUNOFLUORESCENT STAINING 
Huh 7.5.1 cells were seeded at approximately 0.05 x 106 cells/well in a 24-well plate covered 
with collagen-coated coverslips and maintained in complete DMEM medium at 37° C and 5% 
CO2. Next day, the kinase plasmids were transfected into Huh 7.5.1 by using Lipofectamine2000 
(Invitrogen) and subsequently subjected to JFH-AM2 virus infection for two hours. After 48 
hours post infection, samples were washed 3 times in 1X PBS (Invitrogen) for 3 minutes. Cells 
were then fixed in 2% paraformaldehyde (PFA) for 10 minutes and permeabilized with 0.2% 
Triton-X 100 (Biomedicals Inc.) for 10 minutes. Then the cells were incubated for 1 hour in a 
humid chamber with primary antibodies: mouse α-flag (1:1000), human α-HCV E2 (1:200) 
and/or mouse α-NS5A (1:2000). Cells were next washed in 1X PBS 3 times for 10 minutes each 
and secondary antibodies fluorescently conjugated to Alexa Fluor 568, Alexa Fluor 488 and/or 
FITC were used and incubated for another 1 hour in a humid chamber. The coverslips with 
samples were washed with 1X PBS 3 times for 10 minutes each and Draq 5 (Cell Signaling) was 
used to stain the nucleus (1:5000) during the second wash. The coverslips were mounted with 
homemade mounting solution and images were captured using confocal microscopy (Zeiss Meta 
510) using 40x objective lens.       
3.8 PSEUDOPARTICLE PACKAGING SYSTEM 
HCV pseudoparticles (HCVpp) are often used to study viral entry, where the lentiviral particles 
are pseudotyped by the incorporation of the full-length HCV glycoproteins E1 and E2 onto 
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lentiviral or retroviral core particles. HCVpp are useful in that the functional conservation of the 
HCV envelope glycoproteins is maintained.   
 
          293T cells were transfected with pTrip-luc, HIV gag-pol and HCV-E1E2 to generate 
HCVpp or with pTrip-luc, HIV gag-pol and VSV-G for the control VSV-G pseudotype. The 
virus in the supernatant was harvested after 48 hours and the virus was used to infect Huh 7.5.1 
cells, which have been transfected by the kinase of interest. Lysates were made after 48 hours 
and luciferase readings were obtained with luminometer.     
3.9 RNA ISOLATION 
Trizol (Life technologies) was used to lyse the cells and the samples were isolated by 
phenol/chloroform extraction method according to standard protocol and the resulting total RNA 
were used to perform Real Time RT-PCR. 
3.10 REAL-TIME RT-PCR 
Cellular RNAs were reverse-transcribed and PCR amplified using the Power SYBR® Green 
RNA-to-CTTM 1-Step Kit according to the instructions to users with Step-One Real-time PCR 
machine (ABI: Applied Biosystems). Cellular RNAs were normalized to a house-keeping gene 
RPS 11 (40S ribosomal protein 11). The cycling condition was 50° C 10 min (x1), 95° C 5 min 
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(x1), 94° C 10 sec (x40), 56° C 20sec (x40) and 72° C 30 sec (x40). The detailed protocol has 
been published by the Wang laboratory [102]. 
3.11 DETERMINATION OF INTERFERON PRODUCTION 
To explore the effects of kinases on the activation of type I interferon, luciferase reporter assay 
in Huh 7.5.1 cells was used. To this end, an ISRE-luciferase reporter (ISRE-luc, contains 5x 
ISRE from ISG54 promoter upstream of firefly luciferase) construct and an IFN-β luciferase 
reporter construct (p125-luc) were transfected into Huh 7.5.1 cells along with the indicated 
kinase expression plasmid. As a positive control for activation, innate immune signaling plasmid 
encoding the protein MAVS was included in the study. 
 
3.12 NDV-GFP BIOASSAY 
The Huh 7.5.1 cells were transfected with the indicated kinase plasmids and the next day, 50 μl 
of the Newcastle disease virus expressing the enhanced green fluorescent protein NDV-GFP 
virus and 50 μl of 1X PBS was added to each sample and the infection lasted for one hour at 37° 
C. After infection, GFP signal was observed under confocal microscopy (Zeiss Meta 510) using 
40x objective lens, 24 hours post infection.  
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3.13 CELL CYCLE ANALYSIS 
To determine the cell cycle progression, a standard propidium iodide (PI) staining of Huh 7.5.1 
cells expressing individual kinase was used. Flow cytometry was used for analysis.  
3.14 WESTERN BLOTTING 
The lysate of kinase transfected Huh 7.5.1 cells were prepared 48 hours post transfection using 
1X SDS buffer in PBS. The samples were boiled for 5 minutes at 95 °C and loaded on a 15% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by 
transferring onto a nitrocellulose membrane. The kinases were determined by Western blotting 
using mouse anti-flag primary antibody (1:2000). The β-actin protein was used as a loading 
control.    
3.15 CLONING AND SEQUENCING  
Using restriction enzymes, flag-tagged kinase sequence was isolated. The purpose of this 
subcloning was to remove the myristoylation sequence in hopes to express the kinase at higher 
levels. Then PCR was performed on these kinase sequences to amplify the kinase gene and 
ligated into an expression vector pQCXIP between the designated restriction enzyme sites 
(CKS1B: BamHI and EcoRI; MAP2K5: NotI and BamHI; PACSIN1: EcoRI and BamHI). This 
expression vector is a retroviral vector that is often used to express the target gene in various cell 
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lines with unique features including: optimization to remove promoter interference, self-
activation and the hybrid 5’LTR consists of the cytomegalovirus (CMV) type I enhancer and the 
mouse sarcoma virus (MSV) promoter [103-107]. The new subcloned kinase plasmids were then 
isolated and DNA sequenced by the Genomics and Proteomics Core Facility (GPCL) of the 
University of Pittsburgh. Analysis of the sequence was performed in Vector NTI Advance 
software.      
3.16 PCR 
The primers used for the PCR is as follows: 
 
Table 2. Forward and reverse primers of kinases used for PCR 
Kinase Primers 
CKS1B forward: 5’-AGCGGATCCGCCACCATGGACTACAAAGACGATGACGACAAG-3’ 
reverse:  5’-GAGAATTCTCATTTCTTTGGTTTCTTGGGT-3’ 
MAP2K5 forward: 5’-AGCGCGGCCGCGCCACCATGGACTACAAAGACGATGACGACAAG-3’ 
reverse:  5’-GAGGATCCTCACGGGGGCCCTGCTGGCT-3’ 
PACSIN1 forward: 5’-AGCGCGGCCGCGCCACCATGGACTACAAAGACGATGACGACAAG-3’ 
reverse:  5’-GAGAATTCCTAGATAGCCTCCACGTAGTT-3’ 
STK17B forward: 5’-AGCGGATCCGCCACCATGGACTACAAAGACGATGACGACAAG-3’ 
reverse:  5’- GAGAATTCCTAACAGAGCAAATCTGAAAC -3’ 
 
In this PCR, Phusion Hot Start Flex DNA Polymerase Kit was used with the following cycling 
conditions: 98°C for 30 seconds (35 cycles), 98°C for 10 seconds, 70°C for 30 seconds, 72°C for 
30 seconds, 72°C for 5 minutes and 4°C forever.   
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4.0  RESULTS 
 
4.1 PRIMARY SCREENING OF KINASE LIBRARY 
To screen the kinases, primary screening was performed in pools of eight kinases in each group. 
For example, virus pool group 1 had kinases A1 through H1, and virus pool group 2 had kinases 
A2 through H2. A group of uninfected Huh7.5.1 cells were used as a negative control and 
Huh7.5.1 cells infected with HCVcc-luc without expressing any kinases were used as a positive 
control. Another control used was shCl-1, in which the entry factor of HCV is knocked down, 
thus we would expect less infection in this group as shown below. The results of luciferase 
readings showed that virus pool 1 (A1-H1) from plate 1 and virus pool 7 (A7-H7) from plate 2 
showed initial regulatory effects on HCVcc infection, which are determined to be statistically 





Figure 6. Initial screening of the myristoylated kinase library. Huh7.5.1 cells were first infected by retrovirus 
expressing pooled kinases and then by HCVcc-luc (MOI ∼0.1). (A) In plate 1, pool of kinases in group 1 (A1-H1) 
showed inhibitory effects upon HCVcc infection ****p<0.0001 and  (B) in plate 2, pool of kinases in group 7 
(A7-H7) showed enhancing effects on HCVcc infection. Values are expressed as the mean ± SD (n = 2, error bars 
indicate two independent experiments) tested by unpaired t-test * p < 0.05. 
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To rule out the possible contribution of altered cell viability (confounding factor) by expressing 
active kinases, the cellular ATP levels in cells expressing kinases was measured, which reflect 
the cell viability and metabolism, using a Cell Titer Glo luciferase kit. Shown in Figure 7, short-









 Figure 7. Transient expression of kinases did not alter cell viability. Pools of kinases were transiently expressed 
in Huh7.5.1 cells for 48 hours to determine cell viability, which was measured as the ATP levels in viable cells. 
Both plate 1 (A) and plate 2 (B) kinases exhibited no significant cell death observed, when normalized to the 
uninfected cells. Values are expressed as the mean ± SD (n = 2) tested by unpaired t-test. The error bars indicate two 
independent experiments.  
 
4.2 SECONDARY SCREENING OF KINASE LIBRARY 
 
To identify the individual kinase from virus pool 1 (A1-H1) from plate 1 and virus pool 7 (A7-
H7) from plate 2, these statistically significant pools of kinases identified in primary screening 
were further screened by individually packaging the kinases using the lentiviral system as 
described previously. The results represent three independent experiments and statistical 
significance was tested by unpaired t-test (mean ± SD) using Prism software. It was found that 
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three kinases CKS1B (A1), MAP2K5 (C1) and PACSIN1 (H1) from plate 1 consistently 
inhibited HCVcc infection, whereas expression of individual kinase from pool 7 of plate 2 failed 
to consistently enhance HCVcc infection and hence omitted from subsequent evaluations (Figure 




**** **** **** **** 
**** 
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 Figure 8. CKS1B, MAP2K5 and PACSIN1 inhibited HCVcc infection. Kinases in group 1 of plate 1 are 
individually expressed in Huh 7.5.1 cells to determine their effects upon HCVcc-luc infection. (A) Results are 
plotted as relative light unit. (B) Results are plotted as fold of changes (normalized to the mock infected samples, in 
which mock represent only HCVcc infected samples). Values are expressed as mean ± SD (n = 3) ****p<0.0001. 




Figure 9. Individual kinases in pool 7 resulted in no significant effects upon HCVcc infection. Kinases in group 
7 of plate 2 are individually expressed in Huh7.5.1 cells to determine their individual effects upon HCVcc-luc 
infection. (A) Results are plotted as relative light unit. (B) Results are plotted as fold of changes (normalized to the 
mock infected samples). Values are expressed as mean ± SD (n = 3) ****p<0.0001  *p<0.05. The error bars indicate 





4.3 VALIDATION OF SCREENED KINASES BY IMMUNOSTAINING OF HCV 
PROTEINS 
Three kinases that displayed inhibitory effects upon HCVcc infection in the above study were 
chosen for further validation. Kinase expressing Huh7.5.1 cells were infected with wild type 
JFH1 virus (HCVcc) and infected cells were visualized by immunostaining of viral Core and E2 
proteins. Shown in Figure 10, the expression of CKS1B (A1), MAP2K5 (C1) and PACSIN1 
(H1) significantly reduced HCVcc infection in terms of both the number of infected cells and the 
size of the foci. By contrast, expressing the kinase STK17B (B1) or CSNK1A1L- as our negative 
controls, exerted no effect. As a positive control, knocking down HCV entry factor Claudin-1 by 
shRNA (shRNA Cl-1), abolished HCV infection.  
 
Figure 10. Kinases exhibited significant inhibitory effects against HCVcc infection in Huh 7.5.1 cells. 
Approximately 4x104 cells were seeded on collagen-coated glass cover slips in 24-well plate and the cells were then 
infected by JFH1-based HCVcc (MOI ∼0.3). 48 hours post-infection, cells were stained for HCV E2 (red), HCV 
NS5A (green) and nuclei (blue) and imaged under confocal microscope. The images are representatives of at least 
five independent experiments.  
 40 
           To investigate whether the observed effects are specific for HCV, an evaluation of how 
these active kinases affect Dengue virus (DENV) infection was performed.  Using a prototype 
DENV2 virus, which was propagated in the laboratory, as demonstrated in Figure 11, it was 
found that none of the three kinases (CKS1B, MAP2K5 and PACSIN1) exhibited any inhibitory 
effect upon DENV2 infection (MOI 1 and 0.1 (not shown)). 
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 Figure 11. Kinases did not exhibit effects upon Dengue infection. Huh7.5.1 were first infected by retrovirus 
expressing individual kinase for 24 hours followed by infection with DENV2 (Thailand 16681strain) (MOI = 1). 
Infected cells were stained for the presence of viral protein prM (2H2 antibody) (red).  Nuclei were stained by Draq 
5 (blue) and images were taken by using Zeiss Meta LSM 510 confocal microscope. The images are representatives 
















4.4 DETERMINATION OF WHETHER KINASE AFFECTS VIRAL ENTRY BY 
HIV-HCV PSEUDOPARTICLES (HCVPP) 
 
To determine at what stage of the viral life cycle that the screened kinases are inhibiting, 
pseudoparticles were used in this study, as previously described. As shown in figure 12, the 
kinases did not exhibit any effect on HCV entry upon viral infection. The uninfected Huh7.5.1 
cells were used as a negative control and infected Huh7.5.1 cells not expressing kinases were 
used as a positive control. Additional controls used are shCl-1 and STK17B kinase (kinase in 
plate 1). The infectivity of Huh 7.5.1 cells in HCVpp infected group was comparable to the 
positive control VSV-G infected Huh 7.5.1 cells.    
 
Figure 12. Identified kinases did not inhibit HCV entry. The kinases were transiently expressed in Huh7.5.1 cells 
and subsequently infected with HCVpp, VSV-Gpp, or HCVcc-luc. The % infection from the mock group (parental 
cells) was set to 100. Results are presented as mean ± SD (n = 3).  * p<0.05  *** p<0.001 and ****p<0.0001. The 




4.5 DETERMINATION OF WHETHER KINASE AFFECTS VIRAL REPLICAITON 
BY RT-PCR 
 
As the kinases did not show any effect on HCV entry, their potential roles in regulating other 
stages of viral replication were investigated. For this purpose, individual kinase was expressed 
via retroviral transduction into a HCV full-length replicon cell line named replicon (2-3+), which 
harbors a full-length genotype 1b HCV genome that actively replicates without secreting 
infectious virus. Such a system permits direct assessment of the effect of a kinase on stages of 
viral RNA replication. Shown in Figure 13A, addition of a NS5A inhibitor (DAG114) or 
recombinant IFN-α both inhibited HCV replication by nearly 100 fold. Expressions of CKS1B 
and MAP2K5 also significantly suppressed vRNA levels, although the inhibition exerted by 
MAP2K5 was rather marginal. Lastly, PACSIN1 did not seem to inhibit HCV RNA replication.  
 
          Two kinases that showed inhibition on viral replication (CKS1B and MAP2K5) were 
further evaluated in a dose-dependent experiment for their inhibitory effects. Shown in Figure 
13B, there was an inverse correlation between the amount of kinase plasmid that was transfected 
into replicon cells and the detected vRNA copies. This result corroborated the finding that 
CKS1B and MAP2K5 inhibit HCV viral RNA replication, although the inhibitory effect of 







Figure 13. CKS1B and MAP2K5 supressed HCV RNA replication. Total RNA isolated from kinase expressing 
replicon cells (2-3+) was analyzed by real-time PCR. The positive control treatments added were DAG 114 (a NS5A 
inhibitor) and IFN-α. (A) Cells were retrovirally transduced to express individual kinases. (B) Cells were transfected 
with the indicated amount of plasmid DNA shown above panel B, to achieve a dose-dependent effect. In both A and 
B, viral RNA copies were normalized to the values obtained by measuring a house keeping gene RPS 11 using our 
published protocol. Results are presented as mean ± SD (n = 2).  * p<0.05  ** p<0.01 and ***p<0.001. The error 









4.6 DETERMINE THE POTENTIAL ACTIVATION OF INTERFERON 
PRODUCTION 
 
Kinase-mediated activation of cellular pathways may result in the production of type I interferon, 
which is known to potently inhibit HCV replication. To explore this possibility, luciferase 
reporter assays were performed where the interferon response gene (ISG) promoter-driven 
(IRSE-Luc) and the IFN-beta promoter driven (p125-Luc) luciferase reporter constructs were co-
transfected into Huh7.5.1 cells with each kinase construct. Shown in figure 14, whereas MAVS, 
an important signaling molecule downstream of the RIG-I-mediated antiviral pathway [108], 
strongly activated both ISRE-luc and p125-luc, none of the kinases activated the transcription of 
reporter genes, suggesting that signaling from these kinases are not likely to directly induce 
interferon or ISG production. 
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 Figure 14. Expression of kinases did not induce transcription from IFN or ISG promoters. Huh 7.5.1 cells 
were pre-seeded in a 24-well plate. The next day, 0.1 μg of reporter construct was co-transfected with 0.2 μg of 
indicated kinase expression plasmid using lipofectamine 2000 reagent. 48 hours post-transfection, cells were lysed 
and luciferase activity was determined (n=2, SD, standard deviation). pISRE-Luc contains 5 copies of ISRE sites 
from ISG54 promoter upstream of luciferase gene and p125 contains the IFN-α promoter. The error bars represent 
two independent experiments. 
4.7 DETERMINATION OF NDV-GFP BIOASSAY  
As shown previously, none of the kinase constructs activated the transcription of either ISRE-luc 
and p125-luc reporter genes, suggesting that signaling stemming from these kinases are not 
likely to directly induce interferon or ISG production. However, this was further explored to 
validate these results, by performing bioassays to measure the production of type I interferon in 
kinase-expressing Huh 7.5.1 cells using a published protocol that uses a new castle disease virus 
(NDV) that expresses green fluorescent protein (GFP) [109]. In this bioassay, the presence of 
type I IFN suppresses the NDV-GFP infections, resulting in diminish of GFP signal. As shown 
 47 
in Figure 15, whereas addition of recombinant human IFN-α significantly decreased the GFP 
signal, none of the kinases had any effect on NDV-GFP infection. This result confirmed that 
overexpression of kinases in Huh7.5.1 cells did not lead to the production of type I interferon.  
 
 
Figure 15. Kinase expression did not suppress NDV infection. Huh7.5.1 cells that express individual kinase were 
seeded on glass cover slips (24-well plate) and infected by NDV-GFP virus using the protocol described in Methods. 
16 hours post-infection, the cells were fixed and imaged for infection (demonstrated as the expression of GFP). 
Fluorescence was measured by using J software and calculating corrected total cell fluorescence (CTCF). Data 
shown here are the representatives of three independent experiments.  
4.8 DETERMINATION OF WHETHER KINASES ALTER CELL CYCLE 
  
The kinase, CKS1B belongs to the highly conserved cyclin kinase subunit 1 (CKS1) protein 
family, which interacts with cyclin-dependent kinases (CDKs) and controls cell cycle 
progression [110, 111]. HCV replication, at least in cell culture, is known to be affected by cell 
cycle [112]. It has also been reported that HCV infection induces cell cycle arrest at the level of 
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initiation of mitosis [113]. Thus, it was necessary to investigate the effect of these kinases on cell 
cycle progression, to rule out the possibility of cell cycle alteration, by the use of standard 
propidium iodide staining of Huh 7.5.1 cells expressing individual kinase and determine the cell 
cycle progression (existing protocol in Wang Laboratory). Because it was previously observed 
that short-term expression of these active kinases in Huh 7.5.1 cells did not significantly alter 
cell viability/metabolism, it was not highly anticipated that the expression of these kinases would 
significantly alter the cell cycle progression. As predicted, as shown in figure 16, the activated 
kinases did not show any alteration of the cell cycle progression.  
 
 
Figure 16. Kinase expression did not alter cell cycle. Kinase expressing Huh7.5.1 cells were fixed in ethanol and 
stained by propidium iodide (PI). Cell cycle was analyzed by BD Canto flow cytometer. The percentage of cells in 




4.9 LOCALIZATION PATTERN OF ACTIVATED KINASES 
As noted earlier, kinases did not have any effect on viral entry, but CKS1B and MAP2K5 
decreased viral RNA when transfected into replicon cells and RT-PCR was performed. Thus it 
was important to further explain the mechanism of how these activated kinases act to inhibit 
HCV infection. Previous studies have reported that HCV replication is regulated by at least three 
mechanisms: (1) presence of IFN, (2) phosphorylation status of viral NS5A and (3) altered cell 
cycle. However, our interferon production assay and cell cycle analysis did not show  
any significance in the presence of activated kinases.  
 
          To explore the potential effect of kinase activation on the phosphorylation status of HCV 
NS5A, Huh 7.5.1 cells were infected by vaccinia virus expressing T7 polymerase (MOI 3) for 1 
hour followed by transfection of HCVcc-JFH1 construct and individual kinase expression 
plasmids (data not shown). This procedure has been previously published by Qiu and colleagues 
as effectively showing the hyper- and hypo-phosphorylated NS5A (p58 and p56) [91]. It has also 
been reported that hyperphosphorylation of NS5A results in decreased HCV replication [101]. 
However, conflicting observations have also been reported. The results from this experiment also 
resulted in conflicting and inconsistent data; therefore the possibility of the activated kinases 
acting upon NS5A phosphorylation in regulating HCV replication remains inconclusive. It is 
possible that these kinases may be the cellular kinases that directly phosphorylate HCV NS5A in 
vivo, which can be evaluated in the future (data not shown).  
 
          To explore other potential anti-HCV mechanisms, I performed confocal microscopy to 
observe the localization pattern of the activated kinases. The purpose of this experiment was to 
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pinpoint where these kinases are located in the cell and to seek clues as to how they may inhibit 
viral infection. Because there are no commercial antibodies available that give satisfactory 
staining of endogenous kinases, I subcloned individual kinase gene into the retroviral vector 
pQCXIP in which a Flag tag was inserted to the N-terminus of each gene. When transfected into 
293T cells, all constructs allowed expressions of corresponding kinases as demonstrated by 
western blotting (Figure 17). Next, kinase-expressing cells were visualized by confocal 
microscopy. CSK1B displayed a predominantly nuclear localization pattern with a low level of 
cytoplasmic distribution. STK17B exhibited an exclusive nuclear distribution. Both MAP2K5 
and PACSIN1, however, localized to the cytoplasm (Figure 18).  
 
Figure 17. Expression of Flag-tagged kinases in 293T cells. Each kinase was subcloned into retroviral vector 
pQCXIP that contains a Flag tag at the N-terminus of each gene. 0.5 μg plasmid DNA was transfected into 293T 
cells. 48 hours post transfection, total cell lysates were prepared and resolved on a 15% SDS-PAGE followed by 





Figure 18. Cellular distribution of kinases. Flag tagged kinases were expressed in Lenti-X 293T cells and 
immunostained with anti-Flag antibody. Images were taken under a 40X objective using the Carl Zeiss Meta 
LSM510 laser scanning confocal microscope. Nuclei were stained by Draq 5 (blue). The data is a representation of 
at least three independent experiments.    
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4.10 MAP2K5 SURROUNDS LIPID DROPLETS 
MAP2K5 showed only marginal inhibition in HCV RNA replication (Figure. 13), raising the 
possibility that it may have an effect on a post-transcription stage of HCV life cycle. Because of 
its unique cellular localization pattern, I subsequently explored its association with lipid droplets, 
the cellular organelle that is known to be important for virus assembly. Using a dye Bodipy 
(493/503) that specifically stains cellular lipids, I found that MAP2K5 surrounded lipid droplets 
in a manner very similar to HCV core protein (Figure 19 and 20).  
 
Figure 19. Localization of kinases with respect to lipid droplets. Flag-tagged CSK1B, MAP2K5 and PACSIN1 
plasmid was transfected into Huh7.5.1 cells. Cells were fixed and stained for each kinase (red) and then lipid droplet 
(green). For reference, HCV-infected Huh7.5.1 cells were stained for Core and lipid droplet. The data represent two 




Figure 20. MAP2K5 surrounds lipid droplets. 3D scanning of MAP2K5 expressing Huh7.5.1 cells was 
performed. Diagonally projected images (XY, XZ and YZ) are shown here. Consistent with what has been reported, 
HCV core surrounded lipid droplets where the virus assembly occurs. Similarly, MAP2K5 appeared to cover the 
lipid droplets although this does not mean a direct interaction between them. The data represent two independent 
experiments.  
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4.11     PACSIN1 DECREASED THE LEVEL OF P7 
Currently, specific functions to HCV viral proteins have been well documented except for the 
role of the small membrane polypeptide p7. While recent in vivo experiments indicate that p7 is 
essential for infection, subgenomic HCV replicons do not contain p7, illustrating that p7 is not 
necessary for RNA replication [114, 115]. Ectopically expressed, p7 is primarily localized in the 
endoplasmic reticulum as an integral membrane protein and display a topology with both N- and 
C- termini pointing towards the lumen of endoplasmic reticulum [114-116]. NMR experiments 
and molecular dynamics (MD) simulations have recently identified the secondary structure 
elements of p7, and to the construction of a three-dimentional model of the monomer in a 
phospholipid bilayer [114, 117, 118]. In vitro studies have also reported that p7 oligomerizes and 
functions to conduct ions across in artificial membrane systems [114, 118-120]. Experimentally, 
Steinmann and colleagues in 2007 reported that p7 was shown to be critical for virus assembly 
and release, but not essential for its infectivity [114]. Thus, while the basic structural features of 
p7 are becoming gradually known, the exact mechanism of p7 in viral assembly and release, and 
the conditions that lead to the assembly of a functional channel still remains to be better 
understood. 
To investigate the possible effect of kinase expressions in viral protein production, I 
performed co-transfection experiment followed by Western blot analysis. Since PACSIN1 did 
not show any significant effect on viral replication nor did it co-localize with lipid droplets in 
previous experiments, we co-transfected PACSIN1 plasmid with the viral protein plasmids in 
293T cells and see whether that alters the viral protein expression. All ten HCV viral proteins 
were co-transfected with PACSIN1 initially, although only p7 and NS4B are shown in figure 21. 
It was found that the presence of PACSIN1 decreased the expression of HCV p7 in a dose-
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dependent manner. As a loading control β-actin was used and NS4B is included in the figure 
below to show that this effect was specific to p7 but no other viral proteins.  
 
 
Figure 21. PACSIN1 decreased the level of p7. PACSIN1 and p7 were co-transfected in 293T cells, followed by 
Western blotting. As PACSIN1 expression decreased (0.5µg, 0.3µg and 0.2µg), p7 viral protein expression 
increased as shown above indicating inverse relationship. NS4B is shown as a control and β-actin is shown was a 





5.0  DISCUSSION 
The discovery of reversible phosphorylation regulating the activity of glycogen phosphorylase 
has led a great interest in the role of protein phosphorylation in regulating protein function [63]. 
Since then, the near-completion of the human genome sequence has allowed for the 
identification of almost all human protein kinases [63]. To date there are approximately 500-600 
known kinases and open reading frames (ORFs) that are important in regulating cellular 
processes. The protein kinases comprise a large group of enzymes that mostly catalyze the 
covalent attachment of a phosphate group to a protein, and in eukaryotic cells, protein kinases 
mediate most of the signal transduction by modification of substrate activity and control cellular 
processes including but not limited to metabolism, transcription, cell cycle progression, cell 
movement, apoptosis, differentiation, and protein phosphorylation [63].  
 
          HCV infections in particular have been linked to host kinases in the past, and here we 
postulated that these kinases could be the target to control HCV infections. The objective of this 
study was to screen for novel human kinases that may suppress HCV infection through a gain-of-
function approach. This approach is different from the screens in the past, which were siRNA 
screens or chemical-inhibitor based screens (loss-of-function approach).  
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To screen for the kinases of interest, primary screening was performed in pools of eight 
kinases in each group. One may argue that packaging eight kinases instead of packaging 
individually may have brought issues in terms of plasmids competing with each other or not 
being packaged properly, however, it has been observed through previous reports and methods 
set in Wang’s Laboratory, that it is possible to package eight kinases to produce a homogenous 
population of the virus expressing all eight kinases [121]. Also, the infection system we have 
described here is a set protocol known to work in our laboratory, which effectively infects naïve 
Huh 7.5.1 cells to express the kinase.  
 
It was a concern that just because the kinases were packaged and delivered to naïve cells, 
it does not mean that the kinases are automatically activated. However, in this particular study, I 
assume that the kinases are activated because all kinase plasmids have a myristoylation sequence 
and as mentioned earlier, this myristoylation is required for almost all kinases to be activated and 
important for membrane association and recruitment of necessary factors. Also, the fact that I 
observed a significant inhibition of HCV infection from the primary screening, and downstream 
experiments to prove this, I am confident that these kinases are indeed activated. Note that in 
order for a definitive kinase assay however, whether the kinases are being activated or not, 
substrates of the kinases can be used to confirm this, but in our study, the three kinases CKS1B, 
MAP2K5 and PACSIN1 did not have any known substrates available. Another way of 
confirming the activation of kinases would have been to create kinase mutants, and create a 
mutation in the kinase domains, but in this study, we felt that this was beyond the scope of this 
thesis project. Yet another approach to confirm the kinase activation would have been to utilize 
kinase inhibitors, but to my knowledge there are no available inhibitors of CKS1B and 
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PACSIN1, while MAP2K5 inhibitor is rather non-specific. According to the original design, the 
kinases are activated in my study due to presence of the myristoylation sequence. As shown by 
the immunofluorescent stainings, I also demonstrated that these kinases suppress HCV infection, 
but not Dengue virus.  
    
Further functional characterization revealed that the three kinases did not inhibit viral 
entry. However, CKS1B and MAP2K5 both suppressed viral RNA replication although to varied 
degrees. Moreover, MAP2K5 and PACSIN1 may have additional effects on a post-replication 
stage, which will be explored in the future study. At this point, I conclude that at least CSK1B 
primarily inhibits HCV by suppressing viral replication.  
 
Experiments were also performed to explain the mechanism of how these activated 
kinases act to inhibit HCV infection. Since I observed the kinases regulating viral replication, 
previously reported relationship between HCV replication and kinases were investigated and 
these reports have indicated three mechanisms: (1) presence of IFN, (2) phosphorylation status of 
viral NS5A and (3) altered cell cycle. The interferon production assay and cell cycle analysis did 
not show any significant changes in the presence of activated kinases and although data are not 
shown, the potential effect of kinase activation on the phosphorylation status of HCV NS5A was 
also investigated. Previous reports have shown conflicting results and our study also showed 
conflicting and inconsistent data; therefore we ruled the possibility of the activated kinases 
acting upon NS5A phosphorylation in regulating HCV replication as inconclusive. It is possible 
that these kinases may be the cellular kinases that directly phosphorylate HCV NS5A in vivo, 
which can be evaluated in the future. 
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           Because I failed to observe any significance in the aforementioned three main mechanisms 
that have been reported to regulate HCV replication, other possibilities were subsequently 
explored. Through confocal microscopy studies, I determined where these kinases are distributed 
in the cell and attempted to whether they co-localize with viral proteins. Although I have not 
seen co-localization of kinases with viral protein NS5A (data not shown), the immunofluorescent 
staining revealed that MAP2K5 localized to the cytoplasm and surrounded lipid droplets, which 
are known to be the sites of HCV assembly. This result suggests that MAP2K5 may have an 
effect on the viral assembly. Again, it is insufficient to conclude a direct impact on virus 
assembly by MAP2K5 at this stage, a bold and intriguing hypothesis, however, will be: 
MAP2K5 disrupts the virus assembly by phosphorylating a viral target or a host protein.  
 
          In regards to PACSIN1, our study shows that the overexpression of this kinase decreases 
p7 viral protein. The dose-dependent response clearly indicated that as PACSIN1 expression 
increases, p7 viral protein expression significantly decreased. Other viral protein also co-
transfected in this experiment did not show any changes in response to PACSIN1. There are 
many recent reports indicating that p7 functions to conduct ions in artificial membrane systems 
and was experimentally shown to be critical for viral assembly and release. However, the exact 
role that p7 participates in viral assembly and release remains unclear at this time. Thus, we 
speculate that PACSIN1 may modulate HCV infection by down-regulating p7 through unknown 
mechanism.   
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6.0  FUTURE DIRECTIONS 
 
In this project, kinases were thoroughly screened and studied for the mechanism behind how the 
kinases suppress HCV infection. Future experiments could include creating kinase mutants to 
confirm that the kinases used in this study are indeed activated. Also, mechanisms of how these 
kinases are inhibiting HCV infection can be further investigated. In this study, several 
experiments were performed in attempts to investigate kinase mechanism, such as interferon 
production, cell cycle analysis, NS5A phosphorylation and co-localization studies. However, 
there are other possible mechanisms of how kinases suppress HCV infection and these other 
possibilities may be further explored. For example, Immunoprecipitation could be done to 
investigate whether there is a direct interaction between the kinases and HCV viral proteins. 
Specific to MAP2K5, we showed that this kinase might disrupt the virus assembly by localizing 
to the outer surface of lipid droplets. This could be taken further to investigate its effect on virus 




7.0  PUBLIC HEALTH RELEVANCE 
 
HCV is a global concern and the treatments available to patients often times result in poor 
response due to severe side effects and poor patient compliance. Thus, the findings of novel 
kinases suppressing HCV infection reveal much potentials. One of these potentials of course is 
the recognition of previously unidentified inhibitory effects of HCV infection by kinases, but this 
also highlights the potential of combating HCV infection by activating specific kinase-mediated 
pathways. It is also my prediction that the kinase-mediated inhibition of HCV infection would be 
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